Case Series: Successful Visual Recovery in Central Serous Chorioretinopathy with Spironolactone Treatment

 Purpose: To describe clinical outcomes of spironolactone therapy in patients with central serous chorioretinopathy (CSCR).  Methods: We present a case series of three male patients diagnosed with CSCR and treated with oral spironolactone 25 mg/day for three months. All patients underwent baseline and follow-up ophthalmologic evaluation, including uncorrected visual acuity (UCVA) and optical coherence tomography (OCT).  Results: All three patients showed significant anatomical and functional improvements. UCVA improved from 6/40 to 6/15 in Case 1, from 6/40 to 6/7.5 in Case 2, and from 6/40 to 6/8 in Case 3. OCT demonstrated near-complete resorption of subretinal fluid in all cases. No systemic or ocular adverse effects were reported during treatment.  Conclusion: Low-dose spironolactone was effective and well tolerated in CSCR, supporting its potential as a therapeutic option in both acute and persistent cases.